Novogene Announces Completion of RMB 500 Million Series B Financing to Advance Genomics Solutions

Novogene, founded in March 2011, is dedicated to advancing the applications of biology, computer science, and information technology in plant and animal research as well as human health. The company has established the largest high-throughput gene sequencing center in the Asia-Pacific region. Headquartered in Beijing, it operates experimental bases in Tianjin and the United States, and maintains subsidiaries or joint ventures in Hong Kong, the United States, the United Kingdom, and Singapore.

Novogene’s business spans three major sectors: scientific services, oncology genetic testing, and hereditary genetic testing, with its scientific services segment ranking first in market share within China. To date, the company has collaborated with clients to publish more than 200 SCI-indexed articles, including 11 papers in top-tier journals from the Nature and Science families.

In the field of oncology genetic testing, Novogene leverages its comprehensive molecular pathology testing platform to provide precise molecular pathology testing products and services for solid tumors to patients, hospitals, and pharmaceutical companies. Novogene has obtained national medical institution practice licenses and medical device production licenses. Novogene Medical Laboratory has introduced internationally mature management and service systems, established clinical testing laboratories compliant with international CLIA and CAP standards, and continuously develops leading-edge oncology genetic testing products. It offers precision oncology treatment solutions, including guidance on cancer medication, dynamic monitoring, and detection of hereditary cancer susceptibility genes, delivering precise molecular pathology testing products and services for solid tumors to patients, hospitals, and pharmaceutical companies.

In the field of genetic testing, Novogene has developed a series of testing services based on next-generation sequencing (NGS) technology, including preconception genetic testing, newborn genetic screening, and personal genomics products. The company focuses on reproductive health and personal genomics, providing professional genetic counseling services to its clients.

CMB International is a wholly-owned subsidiary of China Merchants Bank (CMB). As the sole direct investment platform under CMB, it bears the responsibility of leveraging the vast emerging domestic financial market through dual linkages between onshore and offshore operations, as well as between investment banking and commercial banking. CMB International has established its business presence in private equity investment, investment fund management, mezzanine fund management, cross-border capital operations, and other innovative financial services. It is committed to building a high-quality comprehensive investment platform and an alternative asset management platform under CMB through development, transformation, and innovation. Since its establishment, CMB International has accurately grasped industry trends, capitalized on emerging opportunities, and led or participated in numerous prominent investment cases within the industry.

SDIC Innovation was established in 2009 as a professional private equity management firm operating independently in accordance with market-oriented principles. Currently, SDIC Innovation manages fund assets exceeding RMB 50 billion, either directly or indirectly. Its managed capital encompasses financial institutions, the National Social Security Fund, as well as state-owned and private capital, making it one of the largest professional private equity management firms in China.

SDIC Innovation takes industrial development and value creation as its core drivers, leveraging an extensive resource network to build a closely connected, mutually beneficial, and virtuously cyclical industrial “ecosystem.” This “ecosystem” encompasses government-industry alignment, finance-enterprise integration, upstream-downstream connectivity across the industry chain, and synergy between management and production, thereby fostering the healthy growth of enterprises. Adhering to the philosophy of value investing, SDIC Innovation focuses on identifying and creating value, striving to closely align the interests of portfolio companies, existing shareholders, and investors. It is committed to providing effective value-added services to portfolio companies, enhancing their core value, and delivering superior returns to fund investors.

Fanghe Capital, established in 2016, is an investment firm focused on high-growth emerging industries. Grounded in in-depth industry research, it continuously explores industry trends and gains insights into the essence of business. Fanghe Capital’s investment focus spans emerging sectors in healthcare, technology, finance, and consumer goods, targeting growth-stage companies from Series A to Series C. Its two founding partners, Ouyang Kun and Zhang Dai, previously oversaw IDG’s media fund and healthcare investments for many years.